Welch & Forbes LLC Has $295,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Welch & Forbes LLC trimmed its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 47.1% during the 4th quarter, HoldingsChannel reports. The firm owned 30,000 shares of the company’s stock after selling 26,750 shares during the quarter. Welch & Forbes LLC’s holdings in Ginkgo Bioworks were worth $295,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DNA. Charles Schwab Investment Management Inc. grew its holdings in shares of Ginkgo Bioworks by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company’s stock valued at $2,295,000 after buying an additional 17,372 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in Ginkgo Bioworks during the 4th quarter valued at about $29,000. SVB Wealth LLC purchased a new position in Ginkgo Bioworks during the 4th quarter valued at about $171,000. Bank of New York Mellon Corp increased its holdings in shares of Ginkgo Bioworks by 48.2% in the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company’s stock valued at $226,000 after purchasing an additional 7,503 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter worth approximately $154,000. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Stock Performance

Shares of DNA opened at $7.56 on Friday. The company has a market capitalization of $434.71 million, a PE ratio of -0.58 and a beta of 1.23. The company’s 50 day moving average price is $11.32 and its 200 day moving average price is $9.30. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $50.40.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.